Compounds > bana-108
Page last updated: 2024-12-08

bana-108

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-(acetylamino)-3-aminobenzoic acid: an aromatic inhibitor of influenza virus neuraminidase; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID446367
CHEMBL ID109162
SCHEMBL ID2344997
MeSH IDM0244115

Synonyms (17)

Synonym
bdbm5274
chembl109162 ,
3-amino-4-acetamidobenzoic acid
bana 108
4-acetamido-3-amino-benzoic acid
bana108
4-(acetylamino)-3-aminobenzoic acid
ST3 ,
4-(acetylamino)-3-amino benzoic acid
DB02268
4-acetamido-3-aminobenzoic acid
AKOS012418429
SCHEMBL2344997
53484-10-9
4-acetylamino-3-amino-benzoic acid
Q27093298
PD008089

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In a mouse model of influenza, 5 did not protect the mice from weight loss due to the influenza virus when dosed intranasally."( Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design.
Babu, YS; Bantia, S; Chand, P; Chu, N; Cole, LB; Kotian, PL; Laver, WG; Montgomery, JA; Pathak, VP; Petty, SL; Shrout, DP; Walsh, DA; Walsh, GM, 1997)		0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NeuraminidaseInfluenza A virus (A/tern/Australia/G70C/1975(H11N9))IC50 (µMol)15,000.00002.50002.50002.5000AID1795763; AID1795764
NeuraminidaseInfluenza B virus (B/Lee/1940)IC50 (µMol)15,000.00000.00100.402810.0000AID1795763; AID1795764
NeuraminidaseInfluenza A virus (A/Singapore/1/1957(H2N2))IC50 (µMol)10,000.00000.00100.00500.0170AID1795763
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID203525The compound was tested in vitro for the inhibitory concentration against influenza B/Mem/89 sialidase from whole virus by MUN assay1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Structure-based inhibitors of influenza virus sialidase. A benzoic acid lead with novel interaction.
AID203519The compound was tested in vitro for the inhibitory concentration against influenza N2 sialidase from whole virus by MUN assay1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Structure-based inhibitors of influenza virus sialidase. A benzoic acid lead with novel interaction.
AID147331Inhibitory activity against N2 neuraminidase subtype2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Comparative binding energy (COMBINE) analysis of influenza neuraminidase-inhibitor complexes.
AID147487In vitro inhibitory activity against neuraminidase2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Simple, intuitive calculations of free energy of binding for protein-ligand complexes. 2. Computational titration and pH effects in molecular models of neuraminidase-inhibitor complexes.
AID203520The compound was tested in vitro for the inhibitory concentration against influenza N2 sialidase from whole virus by fetuin assay1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Structure-based inhibitors of influenza virus sialidase. A benzoic acid lead with novel interaction.
AID1594431Inhibition of C-terminal FLAG-tagged human KDM5A expressed in Sf9 cells at 50 uM pre-incubated for 4 hrs before substrate addition and measured after 1 hr by AlphaScreen assay2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Identification of ortho-hydroxy anilide as a novel scaffold for lysine demethylase 5 inhibitors.
AID147484In vitro inhibitory activity against H1N9 strain of Influenza neuraminidase (membrane) at 3.5 mM concentration1997Journal of medicinal chemistry, Dec-05, Volume: 40, Issue:25
Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design.
AID1795764Neuraminidase Inhibition Assay from Article 10.1016/s0960-894x(99)00318-2: \\Design of benzoic acid inhibitors of influenza neuraminidase containing a cyclic substitution for the N-acetyl grouping.\\1999Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14
Design of benzoic acid inhibitors of influenza neuraminidase containing a cyclic substitution for the N-acetyl grouping.
AID1795763Neuraminidase Inhibition Assay from Article 10.1016/s0968-0896(99)00197-2: \\Hydrophobic benzoic acids as inhibitors of influenza neuraminidase.\\1999Bioorganic & medicinal chemistry, Nov, Volume: 7, Issue:11
Hydrophobic benzoic acids as inhibitors of influenza neuraminidase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (66.67)18.2507
2000's2 (22.22)29.6817
2010's1 (11.11)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.93 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.23 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
4-hydroxybenzoic acid
4-hydroxybenzoic acid : A monohydroxybenzoic acid that is benzoic acid carrying a hydroxy substituent at C-4 of the benzene ring.		1.9910monohydroxybenzoic acidalgal metabolite;
plant metabolite
benzoic acid
Benzoic Acid: A fungistatic compound that is widely used as a food preservative. It is conjugated to GLYCINE in the liver and excreted as hippuric acid.. benzoic acid : A compound comprising a benzene ring core carrying a carboxylic acid substituent.. aromatic carboxylic acid : Any carboxylic acid in which the carboxy group is directly bonded to an aromatic ring.		1.9910benzoic acidsalgal metabolite;
antimicrobial food preservative;
drug allergen;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
human xenobiotic metabolite;
plant metabolite
4-aminobenzoic acid
4-Aminobenzoic Acid: An aminobenzoic acid isomer that combines with pteridine and GLUTAMIC ACID to form FOLIC ACID. The fact that 4-aminobenzoic acid absorbs light throughout the UVB range has also resulted in its use as an ingredient in SUNSCREENS.. 4-ammoniobenzoate : A zwitterion obtained by transfer of a proton from the carboxy to the amino group of 4-aminobenzoic acid.. 4-aminobenzoic acid : An aminobenzoic acid in which the amino group is para to the carboxy group.		1.9910aminobenzoic acid;
aromatic amino-acid zwitterion		allergen;
Escherichia coli metabolite;
plant metabolite
vorinostat
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).		2.2110dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
3-aminobenzoic acid
3-aminobenzoic acid: RN given refers to parent cpd. 3-aminobenzoic acid : An aminobenzoic acid carrying an amino group at position 3.		1.9910aminobenzoic acid
3-hydroxybenzoic acid
3-hydroxybenzoic acid: RN given refers to parent cpd. 3-hydroxybenzoic acid : A monohydroxybenzoic acid that is benzoic acid substituted by a hydroxy group at position 3. It has been isolated from Taxus baccata. It is used as an intermediate in the synthesis of plasticisers, resins, pharmaceuticals, etc.		1.9910monohydroxybenzoic acidbacterial metabolite;
plant metabolite
4-nitroacetanilide
[no description available]		1.9910
sulfacetamide
[no description available]		1.9910
carzenide
[no description available]		1.9910sulfonamide
4-acetylbenzoic acid
4-acetylbenzoic acid: structure in first source		1.9910
3,5-diaminobenzoic acid
3,5-diaminobenzoic acid: RN given refers to parent cpd		1.9910
acedoben
4-acetamidobenzoic acid : A amidobenzoic acid that consists of benzoic acid bearing an acetamido substituent at position 4.		1.9910amidobenzoic acid
3-acetamidobenzoic acid
N-acetyl-m-aminobenzoic acid: from Solanum laciniatum; structure in first source		1.9910
2-deoxy-2,3-dehydro-n-acetylneuraminic acid
2-deoxy-2,3-dehydro-N-acetylneuraminic acid: also known as NeuAc2en, but this is also synonym for another compound. 2-deoxy-2,3-dehydro-N-acetylneuraminic acid : N-Acetylneuraminic acid reduced across the 2,3-bond with loss of the hydroxy group at C-2; it is a minor component of body fluids although abundant in sialuria.		2.9140N-acetylneuraminic acids
4-guanidinobenzoate
4-guanidinobenzoate: RN given refers to parent cpd. 4-guanidinobenzoic acid : Benzoic acid substituted at the para position by a guanidino group.		1.9910benzoic acids;
guanidines
n-acetylneuraminic acid
N-Acetylneuraminic Acid: An N-acyl derivative of neuraminic acid. N-acetylneuraminic acid occurs in many polysaccharides, glycoproteins, and glycolipids in animals and bacteria. (From Dorland, 28th ed, p1518). N-acetylneuraminic acid : An N-acylneuraminic acid where the N-acyl group is specified as acetyl.		1.9810N-acetylneuraminic acidsantioxidant;
bacterial metabolite;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
human metabolite;
mouse metabolite
1-[4-carboxy-2-(3-pentylamino)phenyl]-5,5-bis(hydroxymethyl)pyrrolidin-2-one
1-[4-carboxy-2-(3-pentylamino)phenyl]-5,5-bis(hydroxymethyl)pyrrolidin-2-one : A member of the class of benzoic acids that is benzoic acid in which the hydrogens at positions 3 and 4 have been replaced by pentan-2-ylamino and 2,2-bis(hydroxymethyl)-5-oxopyrrolidin-1-yl groups, respectively.		210benzoic acids;
primary alcohol;
pyrrolidin-2-ones;
secondary amino compound
4-amino-2-deoxy-2,3-didehydro-n-acetylneuraminic acid
[no description available]		2.0110
bana 113
[no description available]		3.0950
oxalylglycine
oxalylglycine: structure given in first source. N-oxalylglycine : An amino dicarboxylic acid that is iminodiacetic acid with an oxo substituent. It is used as an inhibitor of alpha-ketoglutarate dependent (EC 1.14.11.*) enzymes.		2.2110amino dicarboxylic acid;
N-acylglycine		EC 1.14.11.* (oxidoreductase acting on paired donors, 2-oxoglutarate as one donor, incorporating 1 atom each of oxygen into both donors) inhibitor
3-[[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-4-pyrimidinyl]amino]propanoic acid
[no description available]		2.2110organonitrogen heterocyclic compound
ConditionIndicatedRelationship StrengthStudiesTrials